Citi analyst Graham Parry initiated coverage of GSK (GSK) with a Neutral rating and 1,900 GBp price target The firm sees mid-term growth challenges for GSK due to loss of exclusivities.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GSK:
- GSK’s RSV vaccine receives European approval for expanded use
- Drugmakers use AI to help progress through trials, submissions, Reuters says
- GSK announces China’s NMPA approved new indication for Trelegy Ellipta
- GSK Halts Early-Stage Sickle Cell Study, Tweaking the Risk Profile of Its Rare Disease Pipeline
- Moderna Stock (MRNA) Hits a New 52-Week High — Can the Rally Last Through 2026?